Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

8.28
-0.1400-1.66%
Post-market: 8.420.1400+1.69%19:30 EDT
Volume:197.31K
Turnover:1.64M
Market Cap:141.63M
PE:-2.15
High:8.46
Open:8.38
Low:8.22
Close:8.42
52wk High:16.77
52wk Low:8.05
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.59
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:0.66
PE(LYR):-2.60

Loading ...

Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference

TIPRANKS
·
Aug 06

Wave Life Sciences to Present at Upcoming Investor Conferences

GlobeNewswire
·
Aug 04

Circio Strengthens Board With RNA Therapy Veterans Ahead of Clinical Push

TIPRANKS
·
Aug 04

Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy

TIPRANKS
·
Aug 04

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

TIPRANKS
·
Jul 31

Wave Life Sciences’ Earnings Call Highlights RNA Momentum

TIPRANKS
·
Jul 31

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Jul 30

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

GlobeNewswire
·
Jul 23

Atrium Therapeutics Grants New Hire Stock Options for 7,000 Shares at USD 11.76 Exercise Price

Reuters
·
Jul 21

Atrium Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 21

Thalia Therapeutics Targets Clinical-Stage Growth With Sanmirna Deal and RNA Pipeline Push

TIPRANKS
·
Jul 17

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

GlobeNewswire
·
Jul 16

Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)

TIPRANKS
·
Jul 16

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

TIPRANKS
·
Jul 14

Atrium Therapeutics Publishes Investor Presentation on Precision RNA Medicines for Cardiac Diseases

Reuters
·
Jul 14

Atrium Therapeutics Wins FDA IND Clearance for ATR 1072 in Prkag2 Syndrome

Reuters
·
Jul 14

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for Atr 1072 for Treatment of Prkag2 Syndrome

THOMSON REUTERS
·
Jul 14

Atrium Therapeutics - First Participant Expected by End of 2026; Initial Data Anticipated Second Half 2027

THOMSON REUTERS
·
Jul 14

Syngenis banks $4M pre-float to power AI-driven biotech platform

The West Australian
·
Jul 13

Shanghai's Rural Spring Tourism Season Drives 260 Million Yuan in Consumption, Aiming for Sustainable Popularity

Deep News
·
Jul 08